A Phase 1/2 interventional study of CFZ533 and Tacrolimus (Tac) in Kidney Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 14 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-28.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to investigate the safety, tolerability, pharmacokinetics (PK) and potential for CFZ533 to replace calcineurin inhibitors (CNI), while providing a similar rate of acute rejection prophylaxis and renal function in a de novo renal transplant population receiving an allograft from standard criteria donors.
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CFZ533 administered with the contemporary standard of care (SoC) consists of concentration-controlled tacrolimus (Tac), combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
Biological: CFZ533 · Drug: Tacrolimus (Tac) · Drug: Mycophenolate mofetil (MMF) · Drug: Corticosteroids (CS)
CFZ533 administered with mycophenolate mofetil (MMF) and corticosteroids (CS) with anti-IL2 induction
Biological: CFZ533 · Drug: Mycophenolate mofetil (MMF) · Drug: Corticosteroids (CS) · Biological: anti-IL2 Induction
Standard of care (SoC) \[concentration-controlled tacrolimus (Tac) combined with mycophenolate mofetil (MMF) and corticosteroids (CS) with anti-IL2 induction\]
Drug: Tacrolimus (Tac) · Drug: Mycophenolate mofetil (MMF) · Drug: Corticosteroids (CS) · Biological: anti-IL2 Induction
Mean Cmax Pharmacokinetic Parameter- Part I
Pharmacokinetics as defined by the systemic concentrations and Cmax of certain immunosuppressant medications used in Part I
Time frame: Day 1
Mean Tmax Pharmacokinetic Parameter - Part I
Quantify pharmacokinetics of CFZ533 in combination with MMF, CS, and tacrolimus in de novo renal transplant patients during the treatment and follow-up periods.
Time frame: Day 1
Mean AUClast Pharmacokinetic Parameter - Part I
Quantify pharmacokinetics of CFZ533 in combination with MMF, CS, and tacrolimus in de novo renal transplant patients during the treatment and follow-up periods.
Time frame: Day 1
Efficacy as Defined by the Frequency and Severity (Banff Classification) of Treated Biopsy Proven Acute Rejection (tBPAR) Adjudicated Data - Part II
To assess the activity of the investigational arm as compared to the standard of care control arm in de novo renal transplant patients as measured by the frequency and severity of tBPAR as measured on the Banff classification scale. An adjudication was performed on all on cause renal biopsies by an independent expert committee blinded to therapy.
Time frame: 3, 6, 9, and 12 months
Total Soluble CD40 and Total Soluble CD154 Concentrations in Plasma - Part 1
To quantify the change from baseline and recovery of peripheral blood total soluble CD40 and total soluble CD154
Time frame: Baseline to end of study (Day 1, Day 29, Day 337)
Free CD40 and Total CD40 on B Cells - Part II
The magnitude and duration of peripheral blood CD40 occupancy. MESF: molecules of equivalent soluble fluorochrome
Time frame: Baseline to end of study (Day 1/predose)
Anti-CFZ533 Antibodies - Part I
To evaluate the immunogenicity of CFZ533 via the quantitative analysis of anti-CFZ533 antibodies
Time frame: Baseline to end of study
Anti-CFZ533 Antibodies - Part II
To evaluate the immunogenicity of CFZ533 via the quantitative analysis of anti-CFZ533 antibodies
Time frame: Baseline to end of study (screening, baseline, Day 141, Day 225, Day 309, Study Completion)
eGFR - Part II
Renal function as assessed by MDRD (Modification of Diet in Renal Disease) formula. eGFR: Estimated glomerular filtration rate
Time frame: Day 1, Day 29, Day 337,
CFZ533 Plasma PK Concentrations - Part II
Quantify the systemic concentrations of CFZ533 in combination with MMF, CS, and tacrolimus in de novo renal transplant patients during the treatment and follow-up periods. A full pharmacokinetic analysis can be performed on the concentration-time data to evaluate the impact of renal transplantation on the various medications used in the treatment regimen.
Time frame: throughout study period (day 84 to day 336)
Total sCD40 Plasma Concentrations - Part II
To quantify the change from baseline and recovery of peripheral blood total soluble CD40
Time frame: 12 months
In Part 1, patients were enrolled into Arm 1. In Part 2, patients were randomized (2:1) to Arms 2A and 2B.
| Milestone | CFZ533 + TAC + MMF (Part 1) | CFZ533 + MMF (Part 2) | Tac + MMF (Part 2) |
|---|---|---|---|
| Started | 7 | 34 | 18 |
| Completed | 6 | 30 | 13 |
| Not completed | 1 | 4 | 5 |
| Withdrew: Graft loss | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 |
| Withdrew: Physician decision | 1 | 3 | 0 |
Pharmacokinetics as defined by the systemic concentrations and Cmax of certain immunosuppressant medications used in Part I
| ug/mL | CFZ533 + TAC + MMF (Part 1) |
|---|---|
| Mean Cmax Pharmacokinetic Parameter- Part I | 66.3 ± 12.3 |
Quantify pharmacokinetics of CFZ533 in combination with MMF, CS, and tacrolimus in de novo renal transplant patients during the treatment and follow-up periods.
| day | CFZ533 + TAC + MMF (Part 1) |
|---|---|
| Mean Tmax Pharmacokinetic Parameter - Part I | 0.237 (0 to 1.02) |
Quantify pharmacokinetics of CFZ533 in combination with MMF, CS, and tacrolimus in de novo renal transplant patients during the treatment and follow-up periods.
| day*ug/mL | CFZ533 + TAC + MMF (Part 1) |
|---|---|
| Mean AUClast Pharmacokinetic Parameter - Part I | 367 ± 52.0 |
To assess the activity of the investigational arm as compared to the standard of care control arm in de novo renal transplant patients as measured by the frequency and severity of tBPAR as measured on the Banff classification scale. An adjudication was performed on all on cause renal biopsies by an independent expert committee blinded to therapy.
| events | CFZ533 + MMF (Part 2) | Tac + MMF (Part 2) |
|---|---|---|
| Month 3 | 6 | 2 |
| Month 6 | 7 | 3 |
| Month 9 | 7 | 3 |
| Month 12 | 7 | 3 |
To quantify the change from baseline and recovery of peripheral blood total soluble CD40 and total soluble CD154
| ng/ml | sCD40 (Part I) | sCD154 |
|---|---|---|
| Baseline | 4.03 ± 4.08 | 0.125 ± 0.007 |
| Day 1 | 8.86 ± 0.0585 | 0.0585 ± 0.0711 |
| Day 2 | 16.7 ± 4.51 | 0.139 ± 0.193 |
| Day 3 | 24.8 ± 4.47 | 0.157 ± 0.235 |
| Day 4 | 31.3 ± 6.34 | 0.241 ± 0.418 |
| Day 8 | 54.0 ± 11.2 | 0.399 ± 0.636 |
| Day 15 | 84.1 ± 13.8 | 0.0879 ± 0.139 |
| Day 22 | 102 ± 13.9 | 0.0500 ± 0.132 |
| Day 29 | 120 ± 15.7 | 0.225 ± 0.504 |
| Day 36 | 128 ± 19.2 | 0.116 ± 0.2 |
| Day 43 | 145 ± 25.6 | 0.0193 ± 0.0474 |
| Day 50 | 156 ± 6.35 | 0.0478 ± 0.0687 |
| Day 57 | 161 ± 21.2 | 0 ± 0 |
| Day 64 | 163 ± 24.2 | 0.0316 ± 0.0492 |
| Day 71 | 156 ± 19.2 | 0.0148 ± 0.0363 |
| Day 85 | 168 ± 21.4 | 0.0139 ± 0.0340 |
| Day 99 | 155 ± 23.3 | 0 ± 0 |
| Day 113 | 85.7 ± 47.9 | 0.0668 ± 0.164 |
| Day 127 | 12.2 ± 15.7 | 0.0488 ± 0.0697 |
| EoS | 0.918 ± 0.330 | 0.0184 ± 0.0411 |
The magnitude and duration of peripheral blood CD40 occupancy. MESF: molecules of equivalent soluble fluorochrome
| MESF | Free CD40 on Whole Blood B Ceels | Total CD40 on Whole Blood B Cells |
|---|---|---|
| CFZ553 + MMF (Baseline) | 30836.00 ± 13648.69 | 12778.80 ± 7873.76 |
| CFZ553 + MMF (D1 - 6h post dose) | 1623.81 ± 1359.85 | 13806.90 ± 7185.66 |
| CFZ553 + MMF (D15) | 799.62 ± 762.38 | 15160.38 ± 7398.57 |
| CFZ553 + MMF (D 29) | 817.63 ± 1540.16 | 13299.60 ± 6330.89 |
| CFZ553 + MMF (D 57) | 597.13 ± 523.55 | 12234.38 ± 6943.13 |
| CFZ553 + MMF (D 85) | 635.47 ± 614.68 | 9330.86 ± 8484.46 |
| CFZ553 + MMF (D 197) | 3699.0 ± 7298.98 | 2820.72 ± 2347.11 |
| CFZ553 + MMF (253) | 2667.38 ± 6146.86 | 1427.14 ± 740.48 |
| CFZ553 + MMF (EoS) | 176.17 ± 266.82 | 1069.67 ± 809.12 |
| Tac + MMF (Baseline) | 31508.33 ± 12759.49 | 14581.43 ± 9342.79 |
| Tac + MMF (D1 - 6h post dose) | 26437.65 ± 11930.50 | 13715.00 ± 8293.33 |
| Tac + MMF (D15) | 24441.67 ± 9125.93 | 13707.14 ± 6770.14 |
| Tac + MMF (D29) | 27840.00 ± 12106.72 | 12698.75 ± 6002.96 |
| Tac + MMF (D57) | 27994.29 ± 12004.57 | 12583.85 ± 6210.07 |
| Tac + MMF (D85) | 25044.00 ± 10896.65 | 8701.54 ± 4183.00 |
| Tac + MMF (D197) | 21360.00 ± 3155.67 | 2067.60 ± 1617.28 |
| Tac + MMF (D253) | 15752.75 ± 7145.32 | 1750.50 ± 1005.84 |
| Tac + MMF (EoS) | 21200.00 ± 4407.95 | 6276.17 ± 11271.20 |
To evaluate the immunogenicity of CFZ533 via the quantitative analysis of anti-CFZ533 antibodies
| anti-CFZ533 antibodies | CFZ533 + TAC + MMF (Part 1) |
|---|---|
| Anti-CFZ533 Antibodies - Part I | 0 |
To evaluate the immunogenicity of CFZ533 via the quantitative analysis of anti-CFZ533 antibodies
| anti-CFZ533 antibodies | CFZ533 + MMF (Part 2) | Tac + MMF (Part 2) |
|---|---|---|
| Screening | 0 | 0 |
| Baseline | 0 | — |
| Day 141 | 0 | 0 |
| Day 225 | 0 | 0 |
| Day 309 | 0 | 0 |
| Study Completion | 0 | 0 |
Renal function as assessed by MDRD (Modification of Diet in Renal Disease) formula. eGFR: Estimated glomerular filtration rate
| ml/min | CFZ533 + MMF (Part 2) | Tac + MMF (Part 2) |
|---|---|---|
| Day 1 | 9.8 (8.3 to 11.3) | 9.7 (7.7 to 11.8) |
| Day 29 | 55.6 (50.4 to 60.7) | 44.3 (37.2 to 51.4) |
| Day 337 | 58.2 (52.2 to 64.2) | 44.2 (36.1 to 52.3) |
Quantify the systemic concentrations of CFZ533 in combination with MMF, CS, and tacrolimus in de novo renal transplant patients during the treatment and follow-up periods. A full pharmacokinetic analysis can be performed on the concentration-time data to evaluate the impact of renal transplantation on the various medications used in the treatment regimen.
| ug/mL | CFZ533 + MMF (Part 2) |
|---|---|
| Day 84 | 247 ± 58.2 |
| Day 112 | 211 ± 51.8 |
| Day 140 | 178 ± 54.9 |
| Day 168 | 157 ± 57.4 |
| Day 196 | 148 ± 53.1 |
| Day 224 | 147 ± 53.8 |
| Day 252 | 151 ± 35.2 |
| Day 280 | 160 ± 87.7 |
| Day 308 | 132 ± 42.5 |
| Day 336 | 156 ± 85.2 |
| End of study | 133 ± 57.8 |
To quantify the change from baseline and recovery of peripheral blood total soluble CD40
| ng/mL | CFZ533 + MMF (Part 2) | Tac + MMF (Part 2) |
|---|---|---|
| Baseline | 3.02 ± 2.44 | 3.67 ± 2.15 |
| Day 1 | 6.95 ± 4.29 | 1.16 ± 1.15 |
| Day 4 | 24.6 ± 11.0 | 1.16 ± 1.15 |
| Day 15 | 69.6 ± 21.5 | 0.869 ± 1.55 |
| Day 29 | 101 ± 18.9 | 0.362 ± 0.0746 |
| Day 57 | 140 ± 17.4 | 0.438 ± 0.316 |
| Day 85 | 189 ± 76.4 | 0.429 ± 0.324 |
| Day 113 | 215 ± 75.5 | 0.391 ± 0.129 |
| Day 141 | 237 ± 93.1 | 0.453 ± 0.271 |
| Day 169 | 238 ± 80.3 | 0.537 ± 0.215 |
| Day 197 | 253 ± 81.3 | 0.423 ± 0.0908 |
| Day 225 | 258 ± 77.7 | 0.452 ± 0.119 |
| Day 253 | 236 ± 36.5 | 0.457 ± 0.0800 |
| Day 281 | 273 ± 71.3 | 0.455 ± 0.0789 |
| Day 309 | 286 ± 66.0 | 0.454 ± 0.0957 |
| Day 337 | 298 ± 57.4 | 0.411 ± 0.0581 |
| End of Study | 303 ± 59.7 | 0.959 ± 1.88 |
Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 3 years.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CFZ533 + TAC + MMF (Part 1) | 0/7 (0%) | 4/7 (57.1%) | 7/7 (100%) |
| CFZ533 + MMF (Part 2) | 0/34 (0%) | 21/34 (61.8%) | 33/34 (97.1%) |
| Tac + MMF (Part 2) | 0/18 (0%) | 12/18 (66.7%) | 18/18 (100%) |
| Total | 0/59 (0%) | 37/59 (62.7%) | 58/59 (98.3%) |
| Event | CFZ533 + TAC + MMF (Part 1) | CFZ533 + MMF (Part 2) | Tac + MMF (Part 2) | Total |
|---|---|---|---|---|
| VomitingGastrointestinal disorders | 2/7 | 0/34 | 1/18 | 3/59 |
| PyelonephritisInfections and infestations | 0/7 | 2/34 | 3/18 | 5/59 |
| Kidney transplant rejectionImmune system disorders | 0/7 | 5/34 | 1/18 | 6/59 |
| PhotophobiaEye disorders | 1/7 | 0/34 | 0/18 | 1/59 |
| Vision blurredEye disorders | 1/7 | 0/34 | 0/18 | 1/59 |
| Abdominal painGastrointestinal disorders | 1/7 | 1/34 | 0/18 | 2/59 |
| DiarrhoeaGastrointestinal disorders | 1/7 | 1/34 | 1/18 | 3/59 |
| Mouth ulcerationGastrointestinal disorders | 1/7 | 0/34 | 0/18 | 1/59 |
| NauseaGastrointestinal disorders | 1/7 | 0/34 | 0/18 | 1/59 |
| PancreatitisGastrointestinal disorders | 1/7 | 0/34 | 0/18 | 1/59 |
| Event | CFZ533 + TAC + MMF (Part 1) | CFZ533 + MMF (Part 2) | Tac + MMF (Part 2) | Total |
|---|---|---|---|---|
| HypophosphataemiaMetabolism and nutrition disorders | 5/7 | 11/34 | 5/18 | 21/59 |
| NauseaGastrointestinal disorders | 4/7 | 10/34 | 9/18 | 23/59 |
| DiarrhoeaGastrointestinal disorders | 2/7 | 8/34 | 10/18 | 20/59 |
| ConstipationGastrointestinal disorders | 1/7 | 14/34 | 8/18 | 23/59 |
| Wound complicationInjury, poisoning and procedural complications | 0/7 | 11/34 | 8/18 | 19/59 |
| VomitingGastrointestinal disorders | 3/7 | 8/34 | 4/18 | 15/59 |
| Secretion dischargeGeneral disorders | 3/7 | 0/34 | 0/18 | 3/59 |
| BK virus infectionInfections and infestations | 3/7 | 10/34 | 6/18 | 19/59 |
| Incision site painInjury, poisoning and procedural complications | 3/7 | 6/34 | 2/18 | 11/59 |
| HyperglycaemiaMetabolism and nutrition disorders | 3/7 | 4/34 | 4/18 | 11/59 |
The Safety Analysis Set included all patients that received at least one dose of study drug. For Part 2, all patients that received their transplant along with any patient who received study drug but had no transplant were combined.
| Age, Continuous(years) | CFZ533 + TAC + MMF (Part 1) | CFZ533 + MMF (Part 2) | Tac + MMF (Part 2) | Total |
|---|---|---|---|---|
| Mean | 48.1 ± 9.30 | 49.0 ± 15.79 | 53.4 ± 18.01 | 50.1 ± 15.91 |
| Sex: Female, Male(Participants) | CFZ533 + TAC + MMF (Part 1) | CFZ533 + MMF (Part 2) | Tac + MMF (Part 2) | Total |
|---|---|---|---|---|
| Female | 3 | 8 | 6 | 17 |
| Male | 4 | 26 | 12 | 42 |
| Ethnicity (NIH/OMB)(Participants) | CFZ533 + TAC + MMF (Part 1) | CFZ533 + MMF (Part 2) | Tac + MMF (Part 2) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 2 | 20 | 9 | 31 |
| Unknown or Not Reported | 5 | 13 | 9 | 27 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Feb 2015 to primary completion in Nov 2017, 33 months.
Results were first posted in Dec 2018, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Iscalimab · Tacrolimus